Companies › Luxa Biotechnology
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RPESC-RPE-4W RPE stem cell-derived retinal pigment epithelium transplantation | – | Phase 1 | Dry Age-related Macular Degeneration | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04627428 | RPESC-RPE-4W | Phase 1 | Dry Age-related Macular Degeneration | Ophthalmology | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.